Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx). This ...
Topline phase 3 INTerpath-001 trial results show adjuvant intismeran autogene plus pembrolizumab significantly improves RFS and DMFS in resected stage IIB-IV melanoma.
AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion–positive advanced/metastatic NSCLC. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...
FDA fast track status supports accelerated development of PLN-101095 plus pembrolizumab for ICI-refractory solid tumors, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...
The pembrolizumab regimen reduced the risk of disease progression or death by 28% and reduced the risk of death by 24% compared with placebo plus paclitaxel with or without bevacizumab. The Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results